Viking Therapeutics (VKTX) Change in Accured Expenses (2014 - 2026)

Viking Therapeutics has reported Change in Accured Expenses for 13 years, with the latest figure at $1.3 million in Q2 2026.

• Quarterly Change in Accured Expenses fell 90.84% year-over-year to $1.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.5 million (up 17.17% YoY) and the FY2025 annual result came in at $6.2 million, up 6.05% from the prior year.
• Change in Accured Expenses slipped to $1.3 million in Q2 2026 per VKTX's latest filing, from $15.9 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $15.9 million in Q1 2024 and troughed at -$13.6 million in Q2 2024.
• A 5-year average of $1.8 million and a median of $1.0 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses sank 862.72% in 2023, then soared 6472.88% in 2024.
• Over 5 years, Change in Accured Expenses stood at $2.5 million in 2022, then soared by 57.26% to $3.9 million in 2023, then plunged by 299.8% to -$7.8 million in 2024, then jumped by 126.37% to $2.1 million in 2025, then slumped by 35.09% to $1.3 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $1.3 million, $15.9 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.